Group 1 - The core viewpoint of the article highlights the financial performance and stock movement of Lakeshore Biosciences (LSB), indicating a positive trend in both revenue and net profit [1] - As of August 18, LSB's stock price increased by 3.36%, reaching $0.806 per share, with a total market capitalization of $33.2257 million [1] - Financial data shows that by March 31, 2025, LSB's total revenue amounted to 615 million RMB, reflecting a year-on-year growth of 7.24% [1] Group 2 - The net profit attributable to the parent company was reported at -99.9825 million RMB, which represents a significant year-on-year increase of 76.93% [1] - Lakeshore Biosciences is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Insights - Lakeshore Biotech (LSB) experienced a stock price increase of 3.67%, reaching $0.819 per share with a total market capitalization of $33.75 million as of August 16 [1] - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company recorded a net profit attributable to shareholders of -99.98 million RMB, which represents a significant year-on-year increase of 76.93% [1] - Lakeshore Biotech is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd., which focuses on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Biotech (LSB) has shown a positive market performance with a 3.13% increase in stock price, reaching $0.79 per share, and a total market capitalization of $32.55 million [1] Financial Performance - As of March 31, 2025, Lakeshore Biotech reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a significant increase in net profit attributable to shareholders, amounting to -99.98 million RMB, which represents a year-on-year growth of 76.93% [1] Company Overview - Lakeshore Biotech is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotech Co., Ltd. [1] - Beijing Yisheng Biotech Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Biosciences (LSB) has shown a positive stock performance with a 2.38% increase, reaching $0.829 per share, and a total market capitalization of $34.18 million [1] Financial Performance - As of March 31, 2025, Lakeshore Biosciences reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a net loss attributable to shareholders of 99.98 million RMB, which represents a significant year-on-year improvement of 76.93% [1] Company Overview - Lakeshore Biosciences is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Bio (LSB) experienced a significant stock price increase of 10.73%, reaching $0.775 per share, with a total market capitalization of $31.94 million as of August 12 [1] Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company recorded a net loss attributable to shareholders of 99.98 million RMB, which represents a year-on-year improvement of 76.93% [1] Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market response with a 3.03% increase in stock price, reflecting investor confidence in the company's financial performance and growth potential [1]. Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, representing a year-on-year growth of 7.24% [1]. - The company achieved a net profit attributable to shareholders of -99.98 million RMB, which indicates a significant year-on-year increase of 76.93% [1]. Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1]. - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1].

Core Viewpoint - Lakeshore Bio (LSB) shows a positive market performance with a 2.49% increase in stock price, reaching $0.679 per share, and a total market capitalization of $27.9834 million [1] Financial Performance - As of March 31, 2025, Lakeshore Bio reported total revenue of 615 million RMB, reflecting a year-on-year growth of 7.24% [1] - The company experienced a significant increase in net profit attributable to shareholders, amounting to -99.9825 million RMB, which represents a year-on-year growth of 76.93% [1] Company Overview - Lakeshore Bio Technology Co., Ltd. is a Cayman Islands-registered holding company, primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

Group 1 - The stock price of Lakeshore Biosciences (LSB) increased by 19.17% on August 1, reaching $0.90 per share, with a trading volume of $43,400 and a total market capitalization of $37.09 million [1] - As of September 30, 2024, Lakeshore Biosciences reported total revenue of 372 million RMB, representing a year-on-year growth of 36.2% [1] - The net profit attributable to the parent company was 20.58 million RMB, showing a significant year-on-year increase of 111.79% [1] Group 2 - Lakeshore Biosciences is a Cayman Islands-registered holding company primarily operated by its domestic subsidiary, Beijing Yisheng Biotechnology Co., Ltd. [1] - Beijing Yisheng Biotechnology Co., Ltd. is a global biopharmaceutical company focused on the discovery, development, production, and commercialization of next-generation vaccines and therapeutic biologics for infectious diseases and cancer [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Core Viewpoint - LakeShore Biopharma Co., Ltd has announced a share and warrant purchase agreement with an institutional investor, aiming to raise US$15 million through the issuance of ordinary shares and warrants [1] Company Summary - The company is focused on discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer [1] - The agreement involves the issuance of 16,987,542 ordinary shares at a price of US$0.883 per share and 16,987,542 warrants, each allowing the purchase of one ordinary share at an exercise price of US$1.079 over a 36-month period [1] Financial Details - The total amount raised through this private placement is US$15 million, which is exempt from registration under Regulation S of the Securities Act of 1933 [1] - The closing of the private placement is expected to occur soon after the parties agree to the Purchase Agreement, subject to customary conditions [1]